MedTrace Logo

A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

NCT07222761 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 915

Last updated 2026-05-08

No results posted yet for this study

Summary

This study is researching a drug called linvoseltamab (also called "study drug") either given alone or in combination with another anti-myeloma drug called carfilzomib, compared to several standard treatments for progressive Multiple Myeloma (MM) after at least 1 but no more than 3 prior therapies.

The aim of this study is to see if the safety and efficacy of linvoseltamab alone or in combination with carfilzomib can deliver better outcomes (deeper and longer responses that help extend life) than standard treatment options.

The study is looking at several other research questions, including:

* What side effects may happen from taking the study drug
* How much study drug is in the blood at different times
* Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)

Conditions

  • Relapsed and/or Refractory Multiple Myeloma (RRMM)

Interventions

DRUG

Linvoseltamab

Administered per the protocol

DRUG

Carfilzomib

Administered per the protocol

DRUG

Daratumumab

Administered per the protocol

DRUG

Dexamethasone

Administered per the protocol

DRUG

Pomalidomide

Administered per the protocol

DRUG

Bortezomib

Administered per the protocol

Sponsors & Collaborators

Principal Investigators

  • Clinical Trial Management · Regeneron Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-02
Primary Completion
2029-06-15
Completion
2034-09-17
FDA Drug
Yes

Countries

  • United States
  • Australia
  • South Korea
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07222761 on ClinicalTrials.gov